Famtozinameran is a component of a bivalent COVID-19 mRNA vaccine encoding the viral spike protein of Omicron variant lineages BA.4 and BA.5. The Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021.
- Mechanism
- Curator reviewed · 3 references
Famtozinameran comprises a nucleoside-modified mRNA encapsulated in lipid nanoparticles that deliver the mRNA into host cells. The lipid nanoparticle formulation facilitates the delivery of the RNA into human cells. Once inside these cells, the mRNA is translated by host machinery to produce a modified SARS-CoV-2 spike (S) protein - specifically the S protein of the Omicron BA.4/BA.5 variant lineages - which is subsequently recognized by the host immune system. Comirnaty has been shown to elicit both neutralizing antibody and cellular immune responses to the S protein, which helps protect against subsequent SARS-CoV-2 infection.
- Primary indication
- In the US, famtozinameran in combination with tozinameran (Comirnaty Original & Omicron BA.4/BA.5 Bivalent mRNA vaccine), is indicated as a booster dose for active immunization against COVID-19.Curator reviewed · 3 structured indications
- First approval
- Canada, 2022
- Code names
- BNT162B2 Omicron (BA.4/BA.5)
Resolves to
What you can answer from here — as of January 17, 2025
Which other approved drugs treat the same conditions as Famtozinameran, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account